Sildenafil for heart failure does not result in significant improvement in exercise capacity

March 11, 2013

Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil (commercially known as Viagra) for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status, according to a study published online by JAMA. Some studies have suggested that phosphodiesterase-5 inhibitors (a class of drugs that includes sildenafil) may improve cardiovascular function.

with preserved (HFPEF) or diastolic heart failure is a common condition with a high level of illness. "Clinical trials of renin-angiotensin system antagonists have not demonstrated improvement in outcomes or clinical status in HFPEF, and effective therapies are needed," according to background information in the article. " suggest that inhibition of phosphodiesterase-5 (PDE-5) reverses adverse cardiac structural and functional remodeling and enhances vascular, neuroendocrine, and renal function. In clinical studies, PDE-5 inhibitor therapy improved exercise tolerance and clinical status in patients with idiopathic and in and reduced ejection fraction."

Margaret M. Redfield, M.D., of the Mayo Clinic, Rochester, Minn., and colleagues conducted a study to test the hypothesis that, compared with placebo, therapy with the PDE-5 inhibitor sildenafil would improve in HFPEF after 24 weeks of therapy, assessed by the change in peak oxygen consumption. The multicenter, randomized clinical trial included 216 stable outpatients with heart failure, reduced exercise capacity and other certain criteria. Participants were randomized from October 2008 through February 2012 at 26 centers in North America. Sildenafil (n = 113) or placebo (n = 103) was administered orally at 20 mg 3 times daily for 12 weeks, followed by 60 mg 3 times daily for 12 weeks. Follow-up was through August 2012.

The primary end point for the study was change in peak oxygen consumption after 24 weeks of therapy. Secondary end points included change in 6-minute walk distance and a hierarchical composite clinical status score based on time to death, time to cardiovascular or cardiorenal hospitalization, and change in quality of life for participants without cardiovascular or cardiorenal hospitalization at 24 weeks. The median (midpoint) age was 69 years, and 48 percent of patients were women.

The researchers found that at 24 weeks, the median change in peak oxygen consumption from the beginning of the study was not significantly different in patients treated with placebo and patients treated with sildenafil. Also, there were no significant differences in the clinical rank score, change in 6-minute walk distance at 24 weeks, or change in peak or 6-minute walk distance at 12 weeks between treatment groups .

Adverse events occurred in 78 patients (76 percent) who received placebo and 90 patients (80 percent) who received sildenafil. Serious adverse events occurred in 16 patients (16 percent) who received placebo and 25 patients (22 percent) who received sildenafil.

"To our knowledge, [this] trial is the first multicenter study to investigate the effect of PDE-5 inhibition in HFPEF. Contrary to our hypothesis, long-term PDE-5 inhibition in HFPEF had no effect on maximal or submaximal exercise capacity, clinical status, quality of life, left ventricular remodeling, diastolic function parameters, or pulmonary artery systolic pressure. worsened more and NT-proBNP, endothelin-1, and uric acid levels increased more in patients treated with sildenafil. Furthermore, there were more (but not significantly more) patients in the sildenafil group who withdrew consent, died, or were too ill to perform the cardiopulmonary exercise test, and patients treated with sildenafil had a higher incidence of vascular adverse events. These findings do not suggest that therapy with the PDE-5 inhibitor sildenafil provides clinical benefit in the general HFPEF population," the authors write.

Explore further: Long-term use of medication does not improve symptoms for heart failure patients

More information: doi:10.1001/jama.2013.2024

The study is being released early to coincide with its presentation at the American College of Cardiology's annual Scientific Sessions.

Related Stories

Long-term use of medication does not improve symptoms for heart failure patients

February 26, 2013
Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient ...

Efficacy of LCZ696 in patients with heart failure and preserved ejection fraction

August 27, 2012
The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison ...

Sildenafil may benefit children with pulmonary arterial hypertension

October 24, 2011
Sildenafil is currently approved for adult pulmonary arterial hypertension (PAH); however, new research presented at CHEST 2011, the 77th annual meeting of the American College of Chest Physicians (ACCP), shows the drug may ...

The mechanistic effects of spironalactone in diastolic heart failure

August 27, 2012
Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.